Alan is for real. I've known him for years. Peter is involved with the software setting up the hosting of Trust Intelligence.
Depends on your point of view. I've accumulated OMER over 5+ years and am up over 150%. I wish all of my stocks were that bad. :-)
You have less than two weeks to wait to learn the Q2 Omidria revenue numbers. I'm thinking those who expect poor sales data may be in for an eye-opening day.
Maybe we won't have to wait long for a decision. I've been digging into the EMA. It that apparently operates continuously, unlike the monthly-meeting CHMP (with August off). The EMA's Commission will make Omidria's EU authorization decision.
This site indicates the continuous EMA activity .....
http://www.ema.europa.eu/ema/index.jsp? … ts_new.jsp
Since we didn't hear about EMA approval, I checked the EMA "Pending Decisions" website and found there are 22 drugs that got CHMP positive opinions in May and earlier (back to December 2014) that have not been approved yet, so the 67 day rule appears to be "soft". Specifically, 11 drugs that got CHMP positive opinions on May 21st still do not have EC approval.
....... which is truly bizarre, since OMS721 has Alexion's blockbuster Soliris in its crosshairs. A big chunk of ALXN's $47B market cap is ascribed to Soliris' aHUS revenues. Alan Ross posted an interesting article on his OMER blog on Trust Intelligence (Google that), saying that Alexion should buy OMER.
The CUP is already underway ...... " Earlier this year, Omeros announced positive data from the Phase 2 trial and commencement of an investigator-requested compassionate use program for OMS721 to allow extended treatment of patients who completed the trial's four-week dosing."
"17th World Congress of Gastrointestinal Cancer17th World Congress of Gastrointestinal Cancer
July 1-4, 2015
The International Convention Center of Barcelona - Barcelona, Spain
Eric Wachter, PhD will present on July 2 at 10:30am and 4:55pm local time. [4:30am and 10:55am EDT]"
From PVCT .....
"Once the poster has been presented at the Congress [5:00am EDT?], Provectus will provide full details of its contents to the public."
Potential for early news Thursday?
"Significant adverse events were limited to injection site and photosensitivity reactions, and resolved
Omeros signs new licensing agreement, former USAID administrator joins board
Jun 18, 2015, 7:49am PDT
Puget Sound Business Journal
Seattle biopharmaceutical company Omeros hit another big milestone this week, announcing a major licensing deal with international pharmaceutical company Fagron.
Omeros (Nasdaq: OMER), which launched its first commercial product called Omidria in April, went public in 2009 and has 12 drugs in its pipeline including those in preclinical stages.
The company's OMS103, which was involved in the licensing deal with Fagron, is used during arthroscopic surgery. The deal will take OMS103 to market.
This most recent licensing deal, which is only for use within the U.S., Fagron will pay Omeros "a substantial majority share of the gross revenues generated from sales of OMS103 with Omeros also receiving a minimum revenue per vial sold," according to a press release.
Fagron will also pay Omeros up to $10 million in commercial milestones, some of which will be received by Omeros as revenue-share enhancement on early sales, the company said.
Omeros also announced this week that Dr. Rajiv Shah, the former administrator for the U.S. Agency for International Development (USAID) has been appointed to the company's board of directors.
"We are pleased to welcome Raj to our board – he brings an outstanding scientific background together with a proven track record of innovation in leading the world's premier development organization," said Dr. Gregory A. Demopulos, chairman and chief executive officer of Omeros, in a statement. "While at USAID, Raj creatively forged strategic partnerships with corporations and private capital to address some of the most pressing global problems, and he is a valuable addition to our team as we continue to expand our development and commercial activities."
That's a fair question, t_c16. His public profile is a significant cut above typical board members at microcap biotechs. I'd suggest his background is certainly as valuable as OMER Director Ray Aspiri's ...... "Chairman of the Board of Directors at Tempress Technologies, Inc., a research and development company specializing in high-pressure fluid dynamics for the oil and gas industry".
SEATTLE, June 17, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that Rajiv Shah, M.D., recent Administrator of the United States Agency for International Development (USAID), has been appointed to serve on the company's board of directors.
From 2010 to 2015, Dr. Shah served as Administrator of USAID, the U.S. government agency responsible for administering civilian foreign aid. During his tenure, Dr. Shah led the efforts of nearly 10,000 staff in more than 70 countries around the world to advance USAID's mission of ending extreme poverty and promoting resilient, democratic societies.
"We are pleased to welcome Raj to our board - he brings an outstanding scientific background together with a proven track record of innovation in leading the world's premier development organization," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "While at USAID, Raj creatively forged strategic partnerships with corporations and private capital to address some of the most pressing global problems, and he is a valuable addition to our team as we continue to expand our development and commercial activities."
"I am honored to join the Omeros board," said Dr. Shah. "With its strong leadership, Omeros is executing on its integrated strategy of commercial success with Omidria® to advance its deep and exciting pipeline of clinical and preclinical small-molecule and protein therapeutic programs. The strength of science and translational capabilities at Omeros are impressive, and I look forward to contributing to the future growth and direction of the company."
Note that once OMS103 is made available commercially by Fagron, it will be able to be used for all surgeries where inflammation and pain management are desired ....... open heart, joint replacements, spinal surgeries, accident injury treatments, etc. etc. etc.
Up 750,000 shares in the latest 2-week reporting period. Now just a hair below ten million shares ...... over 25% of the outstanding shares.
Meanwhile, institutions own over 50%.
Somebody is making a serious mistake and my money says it's the shorts.
......... "SOMEBODY" is going to develop ...... or be recognized as having ....... an ablative immunotherapy drug that is highly efficacious in treating solid tumors and:
1) It requires no assessment of patients' gene defects.
2) One off-the-shelf formulation can be used to treat all patients.
3) It has insignificant side effects.
4) It can be administered to all accessible tumors on an outpatient basis.
5) It has a low production cost and is easy to store and transport.
Mark my words: you can count on this happening.